Company Statements

April 04, 2012 Merck Statement On NASONEX® (mometasone furoate monohydrate) Patent Trial in the U.S. District Court for the District of New Jersey
March 28, 2012 Merck Provides Update on IMPROVE-IT Trial
March 20, 2012 Merck and ARIAD Pharmaceuticals Provide Update on FDA Advisory Committee Vote on Investigational Medicine Ridaforolimus for the Treatment of Metastatic Soft-Tissue or Bone Sarcomas
March 5, 2012 Merck Provides U.S. Regulatory Update on Investigational Ezetimibe/Atorvastatin Tablets
Feb. 28, 2012 Merck Provides Information on FDA Post-Marketing Requirement for Sitagliptin
Feb. 27, 2012 Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in New Jersey
Oct. 12, 2011 Full Federal Court Rules in MSD Australia's Favour in Vioxx® Case
Sept. 13, 2011 Merck Statement on GARDASIL®
Sept. 13, 2011 Merck Provides Update on the IMPROVE-IT Trial
Jul. 1, 2011 Merck Statement on Voluntary Submission of Clinical Research Protocols for its Investigational and Approved Products
Oct. 28, 2010 Merck Statement on Investigation of PCV Presented at Advisory Committee on Immunization Practices Meeting
Oct. 14, 2010 Merck Statement on Remicade and Simponi Arbitration
March 19, 2010 Merck Statement on the Safety of Highest Dose of Simvastatin
March 16, 2010 WHO Extends Prequalification of Merck's ROTATEQ® for Global Use
March 11, 2010 Merck Provides Update on the IMPROVE-IT Trial
March 10, 2010 Merck Responds to News Reports about FOSAMAX® (alendronate sodium) Tablets
Feb. 18, 2010 Merck and Novartis Statement in Response to the FDA’s February 18, 2010 Communication Regarding Long-Acting Beta2-Agonists, including FORADIL® AEROLIZER® (formoterol fumarate inhalation powder)
Jan. 7, 2010 Merck Statement on Update Regarding the IMPROVE-IT Trial
Nov. 30, 2009 Merck Argues VIOXX® Case before U.S. Supreme Court
Nov. 23, 2009 Merck Statement on Article in The Archives of Internal Medicine Involving VIOXX®
Oct. 22, 2009 The Supreme Court of Canada Will Not Review the Saskatchewan Court of Appeal Judgment Overturning a Class Certification Order in VIOXX® Action
Oct. 19, 2009 Merck Statement on U.S. Speaker Fees Company Achieves another Milestone in Its Ongoing Transparency Initiative
Sept. 25, 2009 Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin)
Sept. 24, 2009 Merck Statement on HIV Vaccine Trial
Aug. 11, 2009 Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court
July 29, 2009 Statement by Merck & Co., Inc., Regarding FOSAMAX® (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw
June 20, 2009 Merck & Co., Inc. Statement on Medicare Part D Assistance
June 12, 2009 Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR® (montelukast sodium)
Patient Product Information
Derechos reservados ©2012 Merck Sharp & Dohme Corp. Una subsidiaria de Merck & Co., Inc., Kenilworth, NJ, USA. Todos los derechos reservados.

TRUSTe - Click to Verify